Tariff wars to hit popular US-made drugs in China, regulator data shows

China announced on Friday that it would raise its levies on imports of U.S. goods to 125%, hitting back at U.S. President Donald Trump's decision to single out the world's second-largest economy for higher duties. The Trump administration is also currently investigating whether imports of pharmaceutical products threaten U.S. national security, which could be a precursor to slapping tariffs on those products. Big pharmaceutical companies including AstraZeneca, Sanofi, GSK and Eli Lilly have at least one U.S. manufacturing site for their drugs sold in China, records from China's National Medical Products Administration showed.